Acute tumour response to the MEK1/2 inhibitor selumetinib (AZD6244, ARRY-142886) evaluated by non-invasive diffusion-weighted MRI

Mounia Beloueche‐Babari, Simon P. Robinson|British Journal of Cancer|2013

Cited by 23